Skin cancer: melanoma, basal and squamous cell carcinoma | Omicron Clinic<\/title>\n<meta name=\"description\" content=\"Skin cancers include melanoma, basal cell carcinoma and squamous cell carcinoma. Risk factors, ABCDE rule, diagnosis and treatment in Quebec.\">\n<meta name=\"keywords\" content=\"cancer peau, m\u00e9lanome, carcinome basocellulaire, carcinome spinocellulaire, m\u00e9lanome sympt\u00f4mes, m\u00e9lanome traitement, r\u00e8gle ABCDE m\u00e9lanome, cancer peau facteurs risque, immunoth\u00e9rapie m\u00e9lanome, cancer peau Qu\u00e9bec\">\n<link rel=\"preconnect\" href=\"https:\/\/fonts.googleapis.com\">\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Cinzel:wght@600&family=Poppins:wght@400;500;600;700&display=swap\" rel=\"stylesheet\">\n<style>\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Cinzel:wght@600&family=Poppins:wght@400;500;600;700&display=swap');\n.co-wrap * { font-family: 'Poppins', sans-serif; box-sizing: border-box; }\n.co-wrap { max-width: 1100px; margin: 0 auto; padding: 30px 0 60px; margin-top: 10px; }\n.co-label { font-family: 'Cinzel', serif; font-size: 14px; font-weight: bold; letter-spacing: 1px; text-transform: uppercase; color: #4D6577; margin-bottom: 14px; display: block; }\n.co-wrap h1 { font-size: 32px; font-weight: 500; color: #323C52; margin: 0 0 22px; line-height: 1.2; letter-spacing: 0.5px; }\n.co-intro { font-size: 16px; font-weight: 400; line-height: 1.75; color: #4D6577; margin-bottom: 36px; padding-bottom: 32px; border-bottom: 1px solid rgba(77,101,119,.2); }\n.co-wrap h2 { font-size: 20px; font-weight: 600; color: #323C52; margin: 32px 0 12px; letter-spacing: 0.3px; }\n.co-wrap p { font-size: 15px; font-weight: 400; color: #4D6577; line-height: 1.7; margin-bottom: 14px; }\n.co-list { list-style: none; padding: 0; margin: 12px 0 24px; }\n.co-list li { font-size: 15px; font-weight: 400; color: #4D6577; padding: 10px 14px 10px 38px; margin-bottom: 8px; border-radius: 6px; position: relative; background: rgba(77,101,119,.06); border-left: 3px solid #4D6577; }\n.co-list li::before { content: \"\u2713\"; position: absolute; left: 12px; font-weight: 700; color: #4D6577; }\n.co-table { width: 100%; border-collapse: collapse; margin: 14px 0 22px; font-size: 14px; border-radius: 8px; overflow: hidden; table-layout: fixed; }\n.co-table thead tr { background: #323C52; color: #fff; }\n.co-table thead th { padding: 11px 16px; text-align: left; font-weight: 600; font-size: 13px; }\n.co-table tbody tr:nth-child(even) { background: rgba(77,101,119,.06); }\n.co-table tbody tr:nth-child(odd) { background: #fff; }\n.co-table td { padding: 10px 16px; color: #4D6577; border-bottom: 1px solid rgba(77,101,119,.12); font-size: 14px; vertical-align: top; }\n.co-table td:first-child { font-weight: 600; color: #323C52; }\n.co-infobox { display: flex; gap: 12px; background: rgba(77,101,119,.06); border-radius: 8px; border-left: 4px solid #4D6577; padding: 14px 18px; margin: 18px 0 28px; font-size: 14px; font-weight: 400; color: #4D6577; line-height: 1.65; }\n.co-infobox .ico { font-size: 18px; flex-shrink: 0; }\n.co-urgence { background: #fff8f8; border-left: 5px solid #c0392b; border-radius: 6px; padding: 20px 26px; margin: 24px 0 32px; }\n.co-urgence .co-urgence-titre { font-size: 13px; font-weight: 700; color: #c0392b; letter-spacing: 1.5px; text-transform: uppercase; margin-bottom: 10px; }\n.co-urgence p { color: #5a2020; font-size: 14px; margin: 0 0 10px; line-height: 1.7; }\n.co-urgence p:last-child { margin-bottom: 0; }\n.co-disclaimer { font-size: 13px; color: #8a9aaa; font-style: italic; border-top: 1px solid rgba(77,101,119,.15); padding-top: 24px; margin-top: 40px; line-height: 1.6; }\n<\/style>\n<\/head>\n<body>\n<div class=\"co-wrap\">\n <span class=\"co-label\">Dermatology & Oncology<\/span>\n <h1>Skin cancer - Melanoma, basal and squamous cell carcinoma<\/h1>\n\n <div class=\"co-intro\">\n Skin cancers are the most common group of cancers in North America, with around 80,000 new cases in Canada every year, and their incidence has been rising steadily for several decades due to exposure to ultraviolet (UV) light. Three main types are distinguished according to their cell of origin: basal cell carcinoma (BCC - 75-80 % of skin cancers), squamous cell carcinoma (SCC - 15-20 %), and malignant melanoma (5 % of skin cancers, but responsible for 75 % of skin cancer deaths). Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are collectively known as non-melanocytic skin cancers (NMSC) or keratinocytic cancers - they develop from the keratinocytes of the epidermis, progress slowly, rarely metastasize (especially in the case of BCC) and are curable in over 95 % of cases if treated early. Melanoma, which develops from melanocytes in the basal layer of the epidermis, is biologically much more aggressive, with high early metastatic potential - its mortality was very high until the early 2010s, before the therapeutic revolution brought about by immunotherapy (anti-CTLA-4 and anti-PD-1) and targeted anti-BRAF\/MEK therapies, which have transformed the prognosis of metastatic melanoma, with 5-year survival rates rising from less than 10 % to over 40-50 % in BRAF-mutated forms treated with combined therapies. In Quebec and Canada, around 9,000 new melanomas are diagnosed each year, with a lifetime risk of 1 in 75 for men and 1 in 91 for women.\n <\/div>\n\n <h2>Common and specific risk factors<\/h2>\n <table class=\"co-table\">\n <colgroup>\n <col style=\"width:210px;\">\n <col>\n <col style=\"width:180px;\">\n <\/colgroup>\n <thead>\n <tr>\n <th>Risk factor<\/th>\n <th>Mechanism and context<\/th>\n <th style=\"text-align:center;\">Type of cancer concerned<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Chronic UV exposure (sun)<\/td>\n <td>UVB (290-320 nm) induces characteristic C\u2192T mutations on the dipyrimidine bases of keratinocyte and melanocyte DNA - dominant UV mutational signature in all skin cancers; cumulative exposure over a lifetime \u2192 BCC and CSC; episodes of intense sunburn (especially in childhood and adolescence) \u2192 melanoma<\/td>\n <td style=\"text-align:center;\">BCC, CSC, melanoma<\/td>\n <\/tr>\n <tr>\n <td>Tanning booths (artificial UV)<\/td>\n <td>High-intensity UVA (320-400 nm) - melanoma risk increased by 75 % if first used before age 35 (Boniol 2012 meta-analysis); banned for minors in Quebec since 2012 (Public Health Act)<\/td>\n <td style=\"text-align:center;\">Melanoma, BCC, CSC<\/td>\n <\/tr>\n <tr>\n <td>Phototype I-II (fair skin)<\/td>\n <td>Low production of protective melanin (eumelanin) \u2192 increased sensitivity to UV; redheads, blonds, blue or green eyes, freckles, skin that burns easily without tanning - risk 10 to 20 times greater than phototypes V-VI<\/td>\n <td style=\"text-align:center;\">BCC, CSC, melanoma<\/td>\n <\/tr>\n <tr>\n <td>Multiple and atypical nevi<\/td>\n <td>> 50 common nevi \u2192 5-fold increased risk of melanoma; dysplastic (atypical) nevi \u2192 10- to 20-fold increased risk; multiple atypical nevi syndrome (MANS) \u2192 10-fold increased lifetime risk compared to general population<\/td>\n <td style=\"text-align:center;\">Melanoma<\/td>\n <\/tr>\n <tr>\n <td>Personal or family history of melanoma<\/td>\n <td>Personal history \u2192 risk of second melanoma \u00d78; 1st-degree family history \u2192 risk \u00d72-3; CDKN2A (p16) mutations - tumor suppressor gene - in 25-40 % of familial melanomas; CDK4, BAP1, TERT mutations<\/td>\n <td style=\"text-align:center;\">Melanoma<\/td>\n <\/tr>\n <tr>\n <td>Immunodepression<\/td>\n <td>Transplant recipients (chronic immunosuppression) \u2192 risk of BCC \u00d710, CSC \u00d765-250 (especially on precancerous lesion), melanoma \u00d73; advanced HIV; chronic lymphocytic leukemia; prolonged immunosuppressive treatments<\/td>\n <td style=\"text-align:center;\">CSC +++, BCC, melanoma<\/td>\n <\/tr>\n <tr>\n <td>Occupational and environmental exposure<\/td>\n <td>Inorganic arsenic (contaminated water, old pesticides, wood treatment) \u2192 CSC and arsenical keratoses; ionizing radiation (old radiotherapy, radiologist) \u2192 CSC in the irradiated field (20-30 years delay); mineral oils, coal tar, soot (chimney sweeps - first occupational cancer described by Percival Pott 1775)<\/td>\n <td style=\"text-align:center;\">CSC, CBC<\/td>\n <\/tr>\n <tr>\n <td>Chronic precancerous skin lesions<\/td>\n <td>Actinic keratosis (precancerous lesion of CSC - risk of transformation 1-10 % per year); chronic ulcer, burn scar (Marjolin's carcinoma); genital lichen sclerosus; HPV (mucosal and nail carcinomas)<\/td>\n <td style=\"text-align:center;\">CSC<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n\n <h2>Basal cell carcinoma (BCC)<\/h2>\n <ul class=\"co-list\">\n <li>Epidemiology and location: most common cancer in humans - 75-80 % of skin cancers; located in 85 % of cases on the face and neck (sun-exposed areas); nose (one-third of BCCs), cheeks, forehead, eyelids, peri-auricular region; occurs mainly between the ages of 50 and 80; very rarely metastatic (< 0.1 %) but locally destructive if neglected (ulceration of soft tissue and bone - \u00abulcus rodens\u00bb).<\/li>\n <li>Clinical forms: nodular BCC (most frequent form - 60 %): translucent pearly papule with rolled edges, telangiectatic vessels visible on surface, center may ulcerate (ulcero-nodular BCC); superficial BCC (20 %): slightly scaly erythematous plaque, fine pearly edges, trunk and limbs - often multifocal; sclerodermiform BCC (morpheiform - 10 %): ill-defined, pearly-white, indurated plaque, highly infiltrative, histological margins difficult to define - form at high risk of recurrence; pigmented BCC: pigmented variant of nodular - differential diagnosis with melanoma (presence of characteristic pearly margins).<\/li>\n <li>Diagnosis: clinical + dermoscopy (maple leaf structures, egg nests, tree-like telangiectasias, structured white-grey areas); confirmatory skin biopsy before treatment; MRI if there is any doubt about deep invasion (recurrent scleroderma forms).<\/li>\n <li>Treatment : surgical excision with safety margins (4-6 mm for low-risk forms, 3-5 mm for high-risk forms) - reference treatment with cure rate > 95 %; Mohs surgery (controlled micrography) - for high-risk forms (scleroderma, recurrent, high-risk location - nose, eyelids, lips, ears) - histological margins controlled intraoperatively, recurrence rate < 1 % ; topical treatment (vismodegib - hedgehog inhibitor - for advanced or metastatic unresectable BCCs); topical imiquimod and topical 5-FU for superficial BCCs; cryotherapy and curettage-electrocoagulation for small, low-risk superficial lesions.<\/li>\n <\/ul>\n\n <h2>Squamous cell carcinoma (SCC)<\/h2>\n <ul class=\"co-list\">\n <li>Epidemiology and localization: 15-20 % of skin cancers; metastatic risk significantly higher than BCC (1-5 % on average, up to 30-40 % for high-risk forms - lip, ear, scar, immunocompromised); localized mainly on photo-exposed areas (lower lip, auricle, dorsum of hands, forearms, scalp of bald men) and on mucous membranes (lips, tongue, genitals - often associated with HPV).<\/li>\n <li>Forms and clinical presentation : keratotic, crusty, indurated, irregular-edged skin lesion, which may ulcerate - often against a background of sun-damaged skin (dermatoheliosis) or advanced actinic keratosis ; may take on the appearance of an indurated plaque, a chronic non-healing ulcer, or a budding lesion bleeding easily on contact; in situ form (Bowen's disease) - well-defined erythematous scaly plaque without invasion of the dermis - risk of invasive transformation 3-5 % per year<\/li>\n <li>High-risk criteria (unfavorable prognostic factors): thickness > 2 mm (adapted Breslow) or Clark level IV-V; peri-neuronal or vascular invasion; ear, lip, genitalia, scar localization; poorly differentiated histological grade (grade 3-4); size > 2 cm; immunodepression; recurrence.<\/li>\n <li>Treatment : surgical excision with safety margins (4-10 mm depending on risk) - reference treatment; Mohs surgery for high-risk forms in functional or aesthetic areas; sentinel node biopsy if high-risk factors; curettage-electrocoagulation for low-risk in situ forms; cryotherapy for multiple actinic keratoses (primary prevention); imiquimod, topical 5-FU or diclofenac 3 gel % for actinic keratoses; systemic chemotherapy (cisplatin \u00b1 5-FU) or cetuxumab (anti-EGFR) for metastatic or unresectable forms; cemiplimab (anti-PD-1, Libtayo) - approved for advanced cutaneous SCC (2018) - objective response rate 47 %<\/li>\n <\/ul>\n\n <h2>Malignant melanoma<\/h2>\n <ul class=\"co-list\">\n <li>Clinical forms : melanoma with superficial extension (SSM - 70 %) - flat polychromatic lesion with radial growth at first, then late vertical invasion; nodular melanoma (NM - 15 %) - vertical growth from the start, poorer prognosis because often thick at diagnosis ; Dubreuilh melanoma (lentigo maligna melanoma - 10 %) - elderly subject, face, slow horizontal growth on pre-existing lentigo maligna; acral lentiginous melanoma (ALM - 2-5 %) - palms, soles, under the nails (subungual) - more frequent in dark-skinned subjects, where it is the most common melanoma.<\/li>\n <li>ABCDE rule for early detection: A = Asymmetry (one half different from the other); B = Irregular, ill-defined, notched or polycyclic edges; C = Multiple colors in the same lesion (beige, brown, black, red, white, blue) - chromatic heterogeneity; D = Diameter > 6 mm (size of a pencil eraser) - caution: melanomas can be small; E = Evolution - any skin lesion that changes size, shape, color, bleeds or itches should be shown to a doctor; criterion E is the most sensitive and the most important - an evolving lesion justifies a consultation even if the other criteria are not present<\/li>\n <li>Ugly duckling sign: any lesion that stands out from a patient's other nevi - larger, darker, more irregular - merits evaluation independently of ABCDE criteria; some nodular melanomas are symmetrical and monochrome (amelanotic melanoma - pink or flesh) and escape the ABCDE rule.<\/li>\n <li>TNM staging (AJCC 8th edition 2017): T = Breslow thickness (mm) and ulceration; N = nodes; M = distant metastases; stage T1a ( 97 % at 5 years; stage IV (M1c - visceral metastases) - median survival 6-9 months without treatment, 12-24 months with immunotherapy, 36-48 months with anti-BRAF\/MEK (BRAF-mutated) targeted therapies.<\/li>\n <li>Molecular alterations and biomarkers : BRAF V600E mutation - present in 40-50 % of cutaneous melanomas (50 % V600E, 10-15 % V600K, 5-6 % V600R) - therapeutic target of BRAF\/MEK inhibitors; NRAS mutation (15-25 %) - no approved targeted therapy but slightly better prognosis with immunotherapy; KIT mutation (5-10 % - acral and mucosal melanomas) - imatinib possible; CCND1 amplification; uveal melanomas (eye) - GNAQ\/GNA11 mutations, highly resistant to treatment<\/li>\n <\/ul>\n\n <h2>Melanoma treatment by stage<\/h2>\n <table class=\"co-table\">\n <colgroup>\n <col style=\"width:150px;\">\n <col>\n <\/colgroup>\n <thead>\n <tr>\n <th>Stadium<\/th>\n <th>Recommended treatment<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Stage 0 (in situ)<\/td>\n <td>Surgical excision with 0.5-1 cm margins - cured in 99 % of cases<\/td>\n <\/tr>\n <tr>\n <td>Stage I-II (localized)<\/td>\n <td>Wide excision with margins of 1 cm (T1) to 2 cm (T2-T4) depending on Breslow thickness; sentinel node biopsy recommended if Breslow \u2265 0.8 mm or ulceration (stage T1b and beyond) - major prognostic information and guides adjuvant treatment; no adjuvant systemic treatment if sentinel node negative (stage IIA-B according to AJCC 8e)<\/td>\n <\/tr>\n <tr>\n <td>Stage III (lymph nodes affected)<\/td>\n <td>Wide excision + lymph node dissection if sentinel node positive (debated); 12-month systemic adjuvant therapy: pembrolizumab (anti-PD-1, KEYNOTE-054) or nivolumab (CheckMate-238) - recurrence risk reduced by 40-50 %; if BRAF V600E\/K mutated: dabrafenib + trametinib (COMBI-AD) - reduced risk of recurrence by 53 %; 5-year survival: 60-75 % depending on substage<\/td>\n <\/tr>\n <tr>\n <td>Stage IV (metastatic) - BRAF-mutated<\/td>\n <td>Anti-BRAF + anti-MEK targeted therapies: vemurafenib + cobimetinib (coBRIM) or dabrafenib + trametinib (COMBI-d\/v) or encorafenib + binimetinib (COLUMBUS) - response rate 65-70 %, median survival 24-30 months; or combined immunotherapy as first-line therapy depending on profile and preference (see below).<\/td>\n <\/tr>\n <tr>\n <td>Stage IV (metastatic) - any BRAF status<\/td>\n <td>Combined immunotherapy ipilimumab (anti-CTLA-4) + nivolumab (anti-PD-1) - CheckMate-067 - response rate 58 %, 5-year survival 52 % (historical), 6.5-year survival 49 %; pembrolizumab monotherapy - KEYNOTE-006 - 5-year survival 35 %; nivolumab monotherapy - CheckMate-066\/037; brain metastases: pembrolizumab or ipilimumab+nivolumab with documented intracranial activity; relatlimab + nivolumab (anti-LAG-3, RELATIVITY-047) - approved FDA 2022<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n\n <div class=\"co-infobox\">\n <span class=\"ico\">\u2139\ufe0f<\/span>\n <span>The ABCDE rule is a tool for detection, not diagnosis - only skin biopsy with anatomopathological analysis can confirm melanoma. Any suspicious lesion should be excised (not scraped, burned or laser-vaporized) in its entirety with a small margin, in order to obtain a complete histological specimen enabling measurement of Breslow thickness - the most important prognostic factor for melanoma. A dermoscopically suspicious lesion should never be treated by cryotherapy or laser without prior biopsy.<\/span>\n <\/div>\n\n <h2>Prevention and photoprotection<\/h2>\n <ul class=\"co-list\">\n <li>Daily sun protection: use a broad-spectrum sunscreen (UVA + UVB) with a protection factor of SPF \u2265 30 (ideally SPF 50+) - apply 15 to 30 minutes before exposure, repeat every 2 hours and after each swim or significant perspiration; apply generously (2 mg\/cm\u00b2 of skin - i.e. approximately 35 mL for the entire body of an adult) - most users apply only 25 to 50 % of the required amount, reducing actual effectiveness<\/li>\n <li>Avoid intense sun exposure during peak hours (10:00 am to 4:00 pm from May to September in Quebec); seek shade; cover-up clothing, wide-brimmed hat (UV protection \u2265 7.5 cm), sunglasses with certified UV filter<\/li>\n <li>Avoid tanning booths at all costs - in Quebec, they're banned for under-18s; artificial tanning is not a \u00abhealthy\u00bb tan - it's the result of a DNA defense response to UV damage, and doesn't effectively protect against subsequent sunburns<\/li>\n <li>Monthly skin self-examination: examine the entire skin surface (with a mirror and the help of a relative for the back and scalp) - note any new or changing lesions according to the ABCDE rule; annual dermatological consultation recommended for high-risk individuals (phototype I-II, numerous nevi, personal or family history of melanoma).<\/li>\n <li>Protecting children: children's skin is particularly vulnerable - sunburn in childhood and adolescence is the most strongly associated risk factor for melanoma; SPF 50+ for children, avoid direct exposure before 6 months, systematic shade and protective clothing<\/li>\n <\/ul>\n\n <div class=\"co-urgence\">\n <div class=\"co-urgence-titre\">Signs requiring immediate consultation<\/div>\n <p>Consult a doctor as soon as possible if you notice a skin lesion that changes rapidly (within a few weeks or months) in size, shape or color, a lesion that bleeds spontaneously or at the slightest touch, a skin wound that doesn't heal within 4 weeks, or any lesion meeting the ABCDE criteria (asymmetry, irregular borders, multiple colors, diameter > 6 mm, evolution). The speed of evolution is the most important criterion - a melanoma can double in size within a few weeks in its aggressive nodular forms. Detection at stage I (Breslow < 1 mm) confers a 5-year survival of over 97 %, compared with less than 20 % at stage IV - every week counts.<\/p>\n <\/div>\n\n <h2>Consult at Clinique Omicron<\/h2>\n <p>Clinique Omicron physicians perform a complete skin examination, use dermoscopy to assess suspicious pigmented lesions, prescribe skin biopsies and refer confirmed skin cancers to partner dermatologists and oncologists for surgical and systemic management. Consultations are available at our points of service in Quebec, as well as via telemedicine. To book an appointment, visit <a href=\"https:\/\/cliniqueomicron.ca\">cliniqueomicron.ca<\/a>.<\/p>\n\n <p class=\"co-disclaimer\">The contents of this page are provided for information purposes only and do not replace the advice of a qualified healthcare professional. Any suspected skin lesion should be evaluated by a physician - biopsy is the only method to confirm or exclude skin cancer.<\/p>\n<\/div>\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron Dermatologie & Oncologie Cancer de la peau \u2014 M\u00e9lanome, carcinome basocellulaire et spinocellulaire Les cancers de la peau constituent le groupe de cancers le plus fr\u00e9quent en Am\u00e9rique du Nord, avec environ 80 000 nouveaux cas au Canada chaque ann\u00e9e, et leur… <a href=\"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/\" rel=\"bookmark\">Read More \"<span class=\"screen-reader-text\">Skin cancer: melanoma, basal and squamous cell carcinoma | Omicron Clinic<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":100,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"_metasync_otto_title":"Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron","_metasync_otto_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","_metasync_otto_keywords":"","_metasync_otto_og_title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","_metasync_otto_og_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","_metasync_otto_twitter_title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","_metasync_otto_twitter_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","rank_math_title":"","rank_math_description":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_aioseo_title":"Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron","_aioseo_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et traitements au Qu\u00e9bec.","_metasync_seo_title":"","_metasync_seo_desc":"","_metasync_breadcrumb_title":"","_metasync_primary_category":0,"_metasync_primary_product_cat":0,"_metasync_otto_disabled":"","_metasync_hreflang":"","_metasync_plugin_sync_ts":"{\"aioseo\":\"2026-05-04T21:42:05+00:00\"}","_metasync_robots_advanced":"","footnotes":""},"class_list":["post-24413","page","type-page","status-publish","hentry"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t<meta name=\"description\" content=\"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...\" \/>\n\t<meta name=\"robots\" content=\"max-snippet:1, max-image-preview:large, max-video-preview:1\" \/>\n\t<meta name=\"google-site-verification\" content=\"yYDMZv-nme7Cg-KrW5GmEWceBTrCDv8zhSkkXdJSnyM\" \/>\n\t<meta name=\"msvalidate.01\" content=\"3225E6935FC4F40C7DDCE56C37141BA8\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 4.9.8\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Clinique Omicron - Clinique M\u00e9dicale\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron\" \/>\n\t\t<meta property=\"og:description\" content=\"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-03-01T02:53:57+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-03-06T23:38:06+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/Clinique Omicron\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@Clinique%20Omicron\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@Clinique%20Omicron\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#listItem\",\"name\":\"Cancer de la peau : m\\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#listItem\",\"position\":2,\"name\":\"Cancer de la peau : m\\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en#listItem\",\"name\":\"Accueil\"}}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#webpage\",\"url\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/\",\"name\":\"Cancer de la peau au Qu\\u00e9bec : m\\u00e9lanome | Clinique Omicron\",\"description\":\"Les cancers de la peau incluent le m\\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\\u00e8gle ABCDE, diagnostic et trai...\",\"inLanguage\":\"en-CA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#breadcrumblist\"},\"datePublished\":\"2026-02-28T22:53:57-04:00\",\"dateModified\":\"2026-03-06T19:38:06-04:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/\",\"name\":\"Clinique Omicron\",\"description\":\"Clinique M\\u00e9dicale\",\"inLanguage\":\"en-CA\",\"publisher\":{\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t\r\n\t\t<title>Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron<\/title>\n\n","aioseo_head_json":{"title":"Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron","description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","canonical_url":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/","robots":"max-snippet:1, max-image-preview:large, max-video-preview:1","keywords":"","webmasterTools":{"google-site-verification":"yYDMZv-nme7Cg-KrW5GmEWceBTrCDv8zhSkkXdJSnyM","msvalidate.01":"3225E6935FC4F40C7DDCE56C37141BA8","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/cliniqueomicron.ca\/en#listItem","position":1,"name":"Accueil","item":"https:\/\/cliniqueomicron.ca\/en","nextItem":{"@type":"ListItem","@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#listItem","name":"Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron"}},{"@type":"ListItem","@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#listItem","position":2,"name":"Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron","previousItem":{"@type":"ListItem","@id":"https:\/\/cliniqueomicron.ca\/en#listItem","name":"Accueil"}}]},{"@type":"WebPage","@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#webpage","url":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/","name":"Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron","description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","inLanguage":"en-CA","isPartOf":{"@id":"https:\/\/cliniqueomicron.ca\/en\/#website"},"breadcrumb":{"@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#breadcrumblist"},"datePublished":"2026-02-28T22:53:57-04:00","dateModified":"2026-03-06T19:38:06-04:00"},{"@type":"WebSite","@id":"https:\/\/cliniqueomicron.ca\/en\/#website","url":"https:\/\/cliniqueomicron.ca\/en\/","name":"Clinique Omicron","description":"Clinique M\u00e9dicale","inLanguage":"en-CA","publisher":{"@id":"https:\/\/cliniqueomicron.ca\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Clinique Omicron - Clinique M\u00e9dicale","og:type":"article","og:title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","og:description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","og:url":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/","og:image":"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg","og:image:secure_url":"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg","article:published_time":"2026-03-01T02:53:57+00:00","article:modified_time":"2026-03-06T23:38:06+00:00","article:publisher":"https:\/\/facebook.com\/Clinique Omicron","twitter:card":"summary_large_image","twitter:site":"@Clinique%20Omicron","twitter:title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","twitter:description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","twitter:creator":"@Clinique%20Omicron","twitter:image":"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg"},"aioseo_meta_data":{"post_id":"24413","title":"Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron","description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","keywords":null,"keyphrases":{"focus":{"keyphrase":"peau","score":75,"analysis":{"keyphraseInTitle":{"score":9,"maxScore":9,"error":0},"keyphraseInDescription":{"score":9,"maxScore":9,"error":0},"keyphraseLength":{"score":9,"maxScore":9,"error":0,"length":1},"keyphraseInURL":{"score":5,"maxScore":5,"error":0},"keyphraseInIntroduction":{"score":9,"maxScore":9,"error":0},"keyphraseInSubHeadings":{"score":3,"maxScore":9,"error":1},"keyphraseInImageAlt":[],"keywordDensity":{"type":"high","score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","og_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":true,"twitter_card":"summary_large_image","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","twitter_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":false,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"1","robots_max_videopreview":"1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"seo_analyzer_scan_date":"2026-04-24 07:33:15","breadcrumb_settings":null,"limit_modified_date":false,"reviewed_by":null,"open_ai":null,"ai":{"faqs":[],"keyPoints":[],"titles":[],"descriptions":[],"socialPosts":{"email":[],"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-03-01 03:13:41","updated":"2026-05-04 17:42:05"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/cliniqueomicron.ca\/en\" title=\"Accueil\">Accueil<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u203a<\/span><span class=\"aioseo-breadcrumb\">\n\tCancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Accueil","link":"https:\/\/cliniqueomicron.ca\/en"},{"label":"Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron","link":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/"}],"_links":{"self":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/comments?post=24413"}],"version-history":[{"count":4,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24413\/revisions"}],"predecessor-version":[{"id":27823,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24413\/revisions\/27823"}],"wp:attachment":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/media?parent=24413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

\n\t\t\t\t

\n\t\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t\n\n\n\n\nSkin cancer: melanoma, basal and squamous cell carcinoma | Omicron Clinic<\/title>\n<meta name=\"description\" content=\"Skin cancers include melanoma, basal cell carcinoma and squamous cell carcinoma. Risk factors, ABCDE rule, diagnosis and treatment in Quebec.\">\n<meta name=\"keywords\" content=\"cancer peau, m\u00e9lanome, carcinome basocellulaire, carcinome spinocellulaire, m\u00e9lanome sympt\u00f4mes, m\u00e9lanome traitement, r\u00e8gle ABCDE m\u00e9lanome, cancer peau facteurs risque, immunoth\u00e9rapie m\u00e9lanome, cancer peau Qu\u00e9bec\">\n<link rel=\"preconnect\" href=\"https:\/\/fonts.googleapis.com\">\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Cinzel:wght@600&family=Poppins:wght@400;500;600;700&display=swap\" rel=\"stylesheet\">\n<style>\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Cinzel:wght@600&family=Poppins:wght@400;500;600;700&display=swap');\n.co-wrap * { font-family: 'Poppins', sans-serif; box-sizing: border-box; }\n.co-wrap { max-width: 1100px; margin: 0 auto; padding: 30px 0 60px; margin-top: 10px; }\n.co-label { font-family: 'Cinzel', serif; font-size: 14px; font-weight: bold; letter-spacing: 1px; text-transform: uppercase; color: #4D6577; margin-bottom: 14px; display: block; }\n.co-wrap h1 { font-size: 32px; font-weight: 500; color: #323C52; margin: 0 0 22px; line-height: 1.2; letter-spacing: 0.5px; }\n.co-intro { font-size: 16px; font-weight: 400; line-height: 1.75; color: #4D6577; margin-bottom: 36px; padding-bottom: 32px; border-bottom: 1px solid rgba(77,101,119,.2); }\n.co-wrap h2 { font-size: 20px; font-weight: 600; color: #323C52; margin: 32px 0 12px; letter-spacing: 0.3px; }\n.co-wrap p { font-size: 15px; font-weight: 400; color: #4D6577; line-height: 1.7; margin-bottom: 14px; }\n.co-list { list-style: none; padding: 0; margin: 12px 0 24px; }\n.co-list li { font-size: 15px; font-weight: 400; color: #4D6577; padding: 10px 14px 10px 38px; margin-bottom: 8px; border-radius: 6px; position: relative; background: rgba(77,101,119,.06); border-left: 3px solid #4D6577; }\n.co-list li::before { content: \"\u2713\"; position: absolute; left: 12px; font-weight: 700; color: #4D6577; }\n.co-table { width: 100%; border-collapse: collapse; margin: 14px 0 22px; font-size: 14px; border-radius: 8px; overflow: hidden; table-layout: fixed; }\n.co-table thead tr { background: #323C52; color: #fff; }\n.co-table thead th { padding: 11px 16px; text-align: left; font-weight: 600; font-size: 13px; }\n.co-table tbody tr:nth-child(even) { background: rgba(77,101,119,.06); }\n.co-table tbody tr:nth-child(odd) { background: #fff; }\n.co-table td { padding: 10px 16px; color: #4D6577; border-bottom: 1px solid rgba(77,101,119,.12); font-size: 14px; vertical-align: top; }\n.co-table td:first-child { font-weight: 600; color: #323C52; }\n.co-infobox { display: flex; gap: 12px; background: rgba(77,101,119,.06); border-radius: 8px; border-left: 4px solid #4D6577; padding: 14px 18px; margin: 18px 0 28px; font-size: 14px; font-weight: 400; color: #4D6577; line-height: 1.65; }\n.co-infobox .ico { font-size: 18px; flex-shrink: 0; }\n.co-urgence { background: #fff8f8; border-left: 5px solid #c0392b; border-radius: 6px; padding: 20px 26px; margin: 24px 0 32px; }\n.co-urgence .co-urgence-titre { font-size: 13px; font-weight: 700; color: #c0392b; letter-spacing: 1.5px; text-transform: uppercase; margin-bottom: 10px; }\n.co-urgence p { color: #5a2020; font-size: 14px; margin: 0 0 10px; line-height: 1.7; }\n.co-urgence p:last-child { margin-bottom: 0; }\n.co-disclaimer { font-size: 13px; color: #8a9aaa; font-style: italic; border-top: 1px solid rgba(77,101,119,.15); padding-top: 24px; margin-top: 40px; line-height: 1.6; }\n<\/style>\n<\/head>\n<body>\n<div class=\"co-wrap\">\n <span class=\"co-label\">Dermatology & Oncology<\/span>\n <h1>Skin cancer - Melanoma, basal and squamous cell carcinoma<\/h1>\n\n <div class=\"co-intro\">\n Skin cancers are the most common group of cancers in North America, with around 80,000 new cases in Canada every year, and their incidence has been rising steadily for several decades due to exposure to ultraviolet (UV) light. Three main types are distinguished according to their cell of origin: basal cell carcinoma (BCC - 75-80 % of skin cancers), squamous cell carcinoma (SCC - 15-20 %), and malignant melanoma (5 % of skin cancers, but responsible for 75 % of skin cancer deaths). Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are collectively known as non-melanocytic skin cancers (NMSC) or keratinocytic cancers - they develop from the keratinocytes of the epidermis, progress slowly, rarely metastasize (especially in the case of BCC) and are curable in over 95 % of cases if treated early. Melanoma, which develops from melanocytes in the basal layer of the epidermis, is biologically much more aggressive, with high early metastatic potential - its mortality was very high until the early 2010s, before the therapeutic revolution brought about by immunotherapy (anti-CTLA-4 and anti-PD-1) and targeted anti-BRAF\/MEK therapies, which have transformed the prognosis of metastatic melanoma, with 5-year survival rates rising from less than 10 % to over 40-50 % in BRAF-mutated forms treated with combined therapies. In Quebec and Canada, around 9,000 new melanomas are diagnosed each year, with a lifetime risk of 1 in 75 for men and 1 in 91 for women.\n <\/div>\n\n <h2>Common and specific risk factors<\/h2>\n <table class=\"co-table\">\n <colgroup>\n <col style=\"width:210px;\">\n <col>\n <col style=\"width:180px;\">\n <\/colgroup>\n <thead>\n <tr>\n <th>Risk factor<\/th>\n <th>Mechanism and context<\/th>\n <th style=\"text-align:center;\">Type of cancer concerned<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Chronic UV exposure (sun)<\/td>\n <td>UVB (290-320 nm) induces characteristic C\u2192T mutations on the dipyrimidine bases of keratinocyte and melanocyte DNA - dominant UV mutational signature in all skin cancers; cumulative exposure over a lifetime \u2192 BCC and CSC; episodes of intense sunburn (especially in childhood and adolescence) \u2192 melanoma<\/td>\n <td style=\"text-align:center;\">BCC, CSC, melanoma<\/td>\n <\/tr>\n <tr>\n <td>Tanning booths (artificial UV)<\/td>\n <td>High-intensity UVA (320-400 nm) - melanoma risk increased by 75 % if first used before age 35 (Boniol 2012 meta-analysis); banned for minors in Quebec since 2012 (Public Health Act)<\/td>\n <td style=\"text-align:center;\">Melanoma, BCC, CSC<\/td>\n <\/tr>\n <tr>\n <td>Phototype I-II (fair skin)<\/td>\n <td>Low production of protective melanin (eumelanin) \u2192 increased sensitivity to UV; redheads, blonds, blue or green eyes, freckles, skin that burns easily without tanning - risk 10 to 20 times greater than phototypes V-VI<\/td>\n <td style=\"text-align:center;\">BCC, CSC, melanoma<\/td>\n <\/tr>\n <tr>\n <td>Multiple and atypical nevi<\/td>\n <td>> 50 common nevi \u2192 5-fold increased risk of melanoma; dysplastic (atypical) nevi \u2192 10- to 20-fold increased risk; multiple atypical nevi syndrome (MANS) \u2192 10-fold increased lifetime risk compared to general population<\/td>\n <td style=\"text-align:center;\">Melanoma<\/td>\n <\/tr>\n <tr>\n <td>Personal or family history of melanoma<\/td>\n <td>Personal history \u2192 risk of second melanoma \u00d78; 1st-degree family history \u2192 risk \u00d72-3; CDKN2A (p16) mutations - tumor suppressor gene - in 25-40 % of familial melanomas; CDK4, BAP1, TERT mutations<\/td>\n <td style=\"text-align:center;\">Melanoma<\/td>\n <\/tr>\n <tr>\n <td>Immunodepression<\/td>\n <td>Transplant recipients (chronic immunosuppression) \u2192 risk of BCC \u00d710, CSC \u00d765-250 (especially on precancerous lesion), melanoma \u00d73; advanced HIV; chronic lymphocytic leukemia; prolonged immunosuppressive treatments<\/td>\n <td style=\"text-align:center;\">CSC +++, BCC, melanoma<\/td>\n <\/tr>\n <tr>\n <td>Occupational and environmental exposure<\/td>\n <td>Inorganic arsenic (contaminated water, old pesticides, wood treatment) \u2192 CSC and arsenical keratoses; ionizing radiation (old radiotherapy, radiologist) \u2192 CSC in the irradiated field (20-30 years delay); mineral oils, coal tar, soot (chimney sweeps - first occupational cancer described by Percival Pott 1775)<\/td>\n <td style=\"text-align:center;\">CSC, CBC<\/td>\n <\/tr>\n <tr>\n <td>Chronic precancerous skin lesions<\/td>\n <td>Actinic keratosis (precancerous lesion of CSC - risk of transformation 1-10 % per year); chronic ulcer, burn scar (Marjolin's carcinoma); genital lichen sclerosus; HPV (mucosal and nail carcinomas)<\/td>\n <td style=\"text-align:center;\">CSC<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n\n <h2>Basal cell carcinoma (BCC)<\/h2>\n <ul class=\"co-list\">\n <li>Epidemiology and location: most common cancer in humans - 75-80 % of skin cancers; located in 85 % of cases on the face and neck (sun-exposed areas); nose (one-third of BCCs), cheeks, forehead, eyelids, peri-auricular region; occurs mainly between the ages of 50 and 80; very rarely metastatic (< 0.1 %) but locally destructive if neglected (ulceration of soft tissue and bone - \u00abulcus rodens\u00bb).<\/li>\n <li>Clinical forms: nodular BCC (most frequent form - 60 %): translucent pearly papule with rolled edges, telangiectatic vessels visible on surface, center may ulcerate (ulcero-nodular BCC); superficial BCC (20 %): slightly scaly erythematous plaque, fine pearly edges, trunk and limbs - often multifocal; sclerodermiform BCC (morpheiform - 10 %): ill-defined, pearly-white, indurated plaque, highly infiltrative, histological margins difficult to define - form at high risk of recurrence; pigmented BCC: pigmented variant of nodular - differential diagnosis with melanoma (presence of characteristic pearly margins).<\/li>\n <li>Diagnosis: clinical + dermoscopy (maple leaf structures, egg nests, tree-like telangiectasias, structured white-grey areas); confirmatory skin biopsy before treatment; MRI if there is any doubt about deep invasion (recurrent scleroderma forms).<\/li>\n <li>Treatment : surgical excision with safety margins (4-6 mm for low-risk forms, 3-5 mm for high-risk forms) - reference treatment with cure rate > 95 %; Mohs surgery (controlled micrography) - for high-risk forms (scleroderma, recurrent, high-risk location - nose, eyelids, lips, ears) - histological margins controlled intraoperatively, recurrence rate < 1 % ; topical treatment (vismodegib - hedgehog inhibitor - for advanced or metastatic unresectable BCCs); topical imiquimod and topical 5-FU for superficial BCCs; cryotherapy and curettage-electrocoagulation for small, low-risk superficial lesions.<\/li>\n <\/ul>\n\n <h2>Squamous cell carcinoma (SCC)<\/h2>\n <ul class=\"co-list\">\n <li>Epidemiology and localization: 15-20 % of skin cancers; metastatic risk significantly higher than BCC (1-5 % on average, up to 30-40 % for high-risk forms - lip, ear, scar, immunocompromised); localized mainly on photo-exposed areas (lower lip, auricle, dorsum of hands, forearms, scalp of bald men) and on mucous membranes (lips, tongue, genitals - often associated with HPV).<\/li>\n <li>Forms and clinical presentation : keratotic, crusty, indurated, irregular-edged skin lesion, which may ulcerate - often against a background of sun-damaged skin (dermatoheliosis) or advanced actinic keratosis ; may take on the appearance of an indurated plaque, a chronic non-healing ulcer, or a budding lesion bleeding easily on contact; in situ form (Bowen's disease) - well-defined erythematous scaly plaque without invasion of the dermis - risk of invasive transformation 3-5 % per year<\/li>\n <li>High-risk criteria (unfavorable prognostic factors): thickness > 2 mm (adapted Breslow) or Clark level IV-V; peri-neuronal or vascular invasion; ear, lip, genitalia, scar localization; poorly differentiated histological grade (grade 3-4); size > 2 cm; immunodepression; recurrence.<\/li>\n <li>Treatment : surgical excision with safety margins (4-10 mm depending on risk) - reference treatment; Mohs surgery for high-risk forms in functional or aesthetic areas; sentinel node biopsy if high-risk factors; curettage-electrocoagulation for low-risk in situ forms; cryotherapy for multiple actinic keratoses (primary prevention); imiquimod, topical 5-FU or diclofenac 3 gel % for actinic keratoses; systemic chemotherapy (cisplatin \u00b1 5-FU) or cetuxumab (anti-EGFR) for metastatic or unresectable forms; cemiplimab (anti-PD-1, Libtayo) - approved for advanced cutaneous SCC (2018) - objective response rate 47 %<\/li>\n <\/ul>\n\n <h2>Malignant melanoma<\/h2>\n <ul class=\"co-list\">\n <li>Clinical forms : melanoma with superficial extension (SSM - 70 %) - flat polychromatic lesion with radial growth at first, then late vertical invasion; nodular melanoma (NM - 15 %) - vertical growth from the start, poorer prognosis because often thick at diagnosis ; Dubreuilh melanoma (lentigo maligna melanoma - 10 %) - elderly subject, face, slow horizontal growth on pre-existing lentigo maligna; acral lentiginous melanoma (ALM - 2-5 %) - palms, soles, under the nails (subungual) - more frequent in dark-skinned subjects, where it is the most common melanoma.<\/li>\n <li>ABCDE rule for early detection: A = Asymmetry (one half different from the other); B = Irregular, ill-defined, notched or polycyclic edges; C = Multiple colors in the same lesion (beige, brown, black, red, white, blue) - chromatic heterogeneity; D = Diameter > 6 mm (size of a pencil eraser) - caution: melanomas can be small; E = Evolution - any skin lesion that changes size, shape, color, bleeds or itches should be shown to a doctor; criterion E is the most sensitive and the most important - an evolving lesion justifies a consultation even if the other criteria are not present<\/li>\n <li>Ugly duckling sign: any lesion that stands out from a patient's other nevi - larger, darker, more irregular - merits evaluation independently of ABCDE criteria; some nodular melanomas are symmetrical and monochrome (amelanotic melanoma - pink or flesh) and escape the ABCDE rule.<\/li>\n <li>TNM staging (AJCC 8th edition 2017): T = Breslow thickness (mm) and ulceration; N = nodes; M = distant metastases; stage T1a ( 97 % at 5 years; stage IV (M1c - visceral metastases) - median survival 6-9 months without treatment, 12-24 months with immunotherapy, 36-48 months with anti-BRAF\/MEK (BRAF-mutated) targeted therapies.<\/li>\n <li>Molecular alterations and biomarkers : BRAF V600E mutation - present in 40-50 % of cutaneous melanomas (50 % V600E, 10-15 % V600K, 5-6 % V600R) - therapeutic target of BRAF\/MEK inhibitors; NRAS mutation (15-25 %) - no approved targeted therapy but slightly better prognosis with immunotherapy; KIT mutation (5-10 % - acral and mucosal melanomas) - imatinib possible; CCND1 amplification; uveal melanomas (eye) - GNAQ\/GNA11 mutations, highly resistant to treatment<\/li>\n <\/ul>\n\n <h2>Melanoma treatment by stage<\/h2>\n <table class=\"co-table\">\n <colgroup>\n <col style=\"width:150px;\">\n <col>\n <\/colgroup>\n <thead>\n <tr>\n <th>Stadium<\/th>\n <th>Recommended treatment<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Stage 0 (in situ)<\/td>\n <td>Surgical excision with 0.5-1 cm margins - cured in 99 % of cases<\/td>\n <\/tr>\n <tr>\n <td>Stage I-II (localized)<\/td>\n <td>Wide excision with margins of 1 cm (T1) to 2 cm (T2-T4) depending on Breslow thickness; sentinel node biopsy recommended if Breslow \u2265 0.8 mm or ulceration (stage T1b and beyond) - major prognostic information and guides adjuvant treatment; no adjuvant systemic treatment if sentinel node negative (stage IIA-B according to AJCC 8e)<\/td>\n <\/tr>\n <tr>\n <td>Stage III (lymph nodes affected)<\/td>\n <td>Wide excision + lymph node dissection if sentinel node positive (debated); 12-month systemic adjuvant therapy: pembrolizumab (anti-PD-1, KEYNOTE-054) or nivolumab (CheckMate-238) - recurrence risk reduced by 40-50 %; if BRAF V600E\/K mutated: dabrafenib + trametinib (COMBI-AD) - reduced risk of recurrence by 53 %; 5-year survival: 60-75 % depending on substage<\/td>\n <\/tr>\n <tr>\n <td>Stage IV (metastatic) - BRAF-mutated<\/td>\n <td>Anti-BRAF + anti-MEK targeted therapies: vemurafenib + cobimetinib (coBRIM) or dabrafenib + trametinib (COMBI-d\/v) or encorafenib + binimetinib (COLUMBUS) - response rate 65-70 %, median survival 24-30 months; or combined immunotherapy as first-line therapy depending on profile and preference (see below).<\/td>\n <\/tr>\n <tr>\n <td>Stage IV (metastatic) - any BRAF status<\/td>\n <td>Combined immunotherapy ipilimumab (anti-CTLA-4) + nivolumab (anti-PD-1) - CheckMate-067 - response rate 58 %, 5-year survival 52 % (historical), 6.5-year survival 49 %; pembrolizumab monotherapy - KEYNOTE-006 - 5-year survival 35 %; nivolumab monotherapy - CheckMate-066\/037; brain metastases: pembrolizumab or ipilimumab+nivolumab with documented intracranial activity; relatlimab + nivolumab (anti-LAG-3, RELATIVITY-047) - approved FDA 2022<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n\n <div class=\"co-infobox\">\n <span class=\"ico\">\u2139\ufe0f<\/span>\n <span>The ABCDE rule is a tool for detection, not diagnosis - only skin biopsy with anatomopathological analysis can confirm melanoma. Any suspicious lesion should be excised (not scraped, burned or laser-vaporized) in its entirety with a small margin, in order to obtain a complete histological specimen enabling measurement of Breslow thickness - the most important prognostic factor for melanoma. A dermoscopically suspicious lesion should never be treated by cryotherapy or laser without prior biopsy.<\/span>\n <\/div>\n\n <h2>Prevention and photoprotection<\/h2>\n <ul class=\"co-list\">\n <li>Daily sun protection: use a broad-spectrum sunscreen (UVA + UVB) with a protection factor of SPF \u2265 30 (ideally SPF 50+) - apply 15 to 30 minutes before exposure, repeat every 2 hours and after each swim or significant perspiration; apply generously (2 mg\/cm\u00b2 of skin - i.e. approximately 35 mL for the entire body of an adult) - most users apply only 25 to 50 % of the required amount, reducing actual effectiveness<\/li>\n <li>Avoid intense sun exposure during peak hours (10:00 am to 4:00 pm from May to September in Quebec); seek shade; cover-up clothing, wide-brimmed hat (UV protection \u2265 7.5 cm), sunglasses with certified UV filter<\/li>\n <li>Avoid tanning booths at all costs - in Quebec, they're banned for under-18s; artificial tanning is not a \u00abhealthy\u00bb tan - it's the result of a DNA defense response to UV damage, and doesn't effectively protect against subsequent sunburns<\/li>\n <li>Monthly skin self-examination: examine the entire skin surface (with a mirror and the help of a relative for the back and scalp) - note any new or changing lesions according to the ABCDE rule; annual dermatological consultation recommended for high-risk individuals (phototype I-II, numerous nevi, personal or family history of melanoma).<\/li>\n <li>Protecting children: children's skin is particularly vulnerable - sunburn in childhood and adolescence is the most strongly associated risk factor for melanoma; SPF 50+ for children, avoid direct exposure before 6 months, systematic shade and protective clothing<\/li>\n <\/ul>\n\n <div class=\"co-urgence\">\n <div class=\"co-urgence-titre\">Signs requiring immediate consultation<\/div>\n <p>Consult a doctor as soon as possible if you notice a skin lesion that changes rapidly (within a few weeks or months) in size, shape or color, a lesion that bleeds spontaneously or at the slightest touch, a skin wound that doesn't heal within 4 weeks, or any lesion meeting the ABCDE criteria (asymmetry, irregular borders, multiple colors, diameter > 6 mm, evolution). The speed of evolution is the most important criterion - a melanoma can double in size within a few weeks in its aggressive nodular forms. Detection at stage I (Breslow < 1 mm) confers a 5-year survival of over 97 %, compared with less than 20 % at stage IV - every week counts.<\/p>\n <\/div>\n\n <h2>Consult at Clinique Omicron<\/h2>\n <p>Clinique Omicron physicians perform a complete skin examination, use dermoscopy to assess suspicious pigmented lesions, prescribe skin biopsies and refer confirmed skin cancers to partner dermatologists and oncologists for surgical and systemic management. Consultations are available at our points of service in Quebec, as well as via telemedicine. To book an appointment, visit <a href=\"https:\/\/cliniqueomicron.ca\">cliniqueomicron.ca<\/a>.<\/p>\n\n <p class=\"co-disclaimer\">The contents of this page are provided for information purposes only and do not replace the advice of a qualified healthcare professional. Any suspected skin lesion should be evaluated by a physician - biopsy is the only method to confirm or exclude skin cancer.<\/p>\n<\/div>\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron Dermatologie & Oncologie Cancer de la peau \u2014 M\u00e9lanome, carcinome basocellulaire et spinocellulaire Les cancers de la peau constituent le groupe de cancers le plus fr\u00e9quent en Am\u00e9rique du Nord, avec environ 80 000 nouveaux cas au Canada chaque ann\u00e9e, et leur… <a href=\"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/\" rel=\"bookmark\">Read More \"<span class=\"screen-reader-text\">Skin cancer: melanoma, basal and squamous cell carcinoma | Omicron Clinic<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":100,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"_metasync_otto_title":"Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron","_metasync_otto_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","_metasync_otto_keywords":"","_metasync_otto_og_title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","_metasync_otto_og_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","_metasync_otto_twitter_title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","_metasync_otto_twitter_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","rank_math_title":"","rank_math_description":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_aioseo_title":"Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron","_aioseo_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et traitements au Qu\u00e9bec.","_metasync_seo_title":"","_metasync_seo_desc":"","_metasync_breadcrumb_title":"","_metasync_primary_category":0,"_metasync_primary_product_cat":0,"_metasync_otto_disabled":"","_metasync_hreflang":"","_metasync_plugin_sync_ts":"{\"aioseo\":\"2026-05-04T21:42:05+00:00\"}","_metasync_robots_advanced":"","footnotes":""},"class_list":["post-24413","page","type-page","status-publish","hentry"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t<meta name=\"description\" content=\"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...\" \/>\n\t<meta name=\"robots\" content=\"max-snippet:1, max-image-preview:large, max-video-preview:1\" \/>\n\t<meta name=\"google-site-verification\" content=\"yYDMZv-nme7Cg-KrW5GmEWceBTrCDv8zhSkkXdJSnyM\" \/>\n\t<meta name=\"msvalidate.01\" content=\"3225E6935FC4F40C7DDCE56C37141BA8\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 4.9.8\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Clinique Omicron - Clinique M\u00e9dicale\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron\" \/>\n\t\t<meta property=\"og:description\" content=\"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-03-01T02:53:57+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-03-06T23:38:06+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/Clinique Omicron\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@Clinique%20Omicron\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@Clinique%20Omicron\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#listItem\",\"name\":\"Cancer de la peau : m\\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#listItem\",\"position\":2,\"name\":\"Cancer de la peau : m\\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en#listItem\",\"name\":\"Accueil\"}}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#webpage\",\"url\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/\",\"name\":\"Cancer de la peau au Qu\\u00e9bec : m\\u00e9lanome | Clinique Omicron\",\"description\":\"Les cancers de la peau incluent le m\\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\\u00e8gle ABCDE, diagnostic et trai...\",\"inLanguage\":\"en-CA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/cancer-peau\\\/#breadcrumblist\"},\"datePublished\":\"2026-02-28T22:53:57-04:00\",\"dateModified\":\"2026-03-06T19:38:06-04:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/\",\"name\":\"Clinique Omicron\",\"description\":\"Clinique M\\u00e9dicale\",\"inLanguage\":\"en-CA\",\"publisher\":{\"@id\":\"https:\\\/\\\/cliniqueomicron.ca\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t\r\n\t\t<title>Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron<\/title>\n\n","aioseo_head_json":{"title":"Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron","description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","canonical_url":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/","robots":"max-snippet:1, max-image-preview:large, max-video-preview:1","keywords":"","webmasterTools":{"google-site-verification":"yYDMZv-nme7Cg-KrW5GmEWceBTrCDv8zhSkkXdJSnyM","msvalidate.01":"3225E6935FC4F40C7DDCE56C37141BA8","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/cliniqueomicron.ca\/en#listItem","position":1,"name":"Accueil","item":"https:\/\/cliniqueomicron.ca\/en","nextItem":{"@type":"ListItem","@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#listItem","name":"Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron"}},{"@type":"ListItem","@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#listItem","position":2,"name":"Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron","previousItem":{"@type":"ListItem","@id":"https:\/\/cliniqueomicron.ca\/en#listItem","name":"Accueil"}}]},{"@type":"WebPage","@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#webpage","url":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/","name":"Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron","description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","inLanguage":"en-CA","isPartOf":{"@id":"https:\/\/cliniqueomicron.ca\/en\/#website"},"breadcrumb":{"@id":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/#breadcrumblist"},"datePublished":"2026-02-28T22:53:57-04:00","dateModified":"2026-03-06T19:38:06-04:00"},{"@type":"WebSite","@id":"https:\/\/cliniqueomicron.ca\/en\/#website","url":"https:\/\/cliniqueomicron.ca\/en\/","name":"Clinique Omicron","description":"Clinique M\u00e9dicale","inLanguage":"en-CA","publisher":{"@id":"https:\/\/cliniqueomicron.ca\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Clinique Omicron - Clinique M\u00e9dicale","og:type":"article","og:title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","og:description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","og:url":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/","og:image":"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg","og:image:secure_url":"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg","article:published_time":"2026-03-01T02:53:57+00:00","article:modified_time":"2026-03-06T23:38:06+00:00","article:publisher":"https:\/\/facebook.com\/Clinique Omicron","twitter:card":"summary_large_image","twitter:site":"@Clinique%20Omicron","twitter:title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","twitter:description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","twitter:creator":"@Clinique%20Omicron","twitter:image":"https:\/\/cliniqueomicron.ca\/wp-content\/uploads\/2025\/12\/unnamed-1-e1765579964732.jpg"},"aioseo_meta_data":{"post_id":"24413","title":"Cancer de la peau au Qu\u00e9bec : m\u00e9lanome | Clinique Omicron","description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","keywords":null,"keyphrases":{"focus":{"keyphrase":"peau","score":75,"analysis":{"keyphraseInTitle":{"score":9,"maxScore":9,"error":0},"keyphraseInDescription":{"score":9,"maxScore":9,"error":0},"keyphraseLength":{"score":9,"maxScore":9,"error":0,"length":1},"keyphraseInURL":{"score":5,"maxScore":5,"error":0},"keyphraseInIntroduction":{"score":9,"maxScore":9,"error":0},"keyphraseInSubHeadings":{"score":3,"maxScore":9,"error":1},"keyphraseInImageAlt":[],"keywordDensity":{"type":"high","score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","og_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":true,"twitter_card":"summary_large_image","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":"Cancer de la peau : m\u00e9lanome, | Brossard | Clinique Omicron","twitter_description":"Les cancers de la peau incluent le m\u00e9lanome, le carcinome basocellulaire et le carcinome spinocellulaire. Facteurs de risque, r\u00e8gle ABCDE, diagnostic et trai...","schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":false,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"1","robots_max_videopreview":"1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"seo_analyzer_scan_date":"2026-04-24 07:33:15","breadcrumb_settings":null,"limit_modified_date":false,"reviewed_by":null,"open_ai":null,"ai":{"faqs":[],"keyPoints":[],"titles":[],"descriptions":[],"socialPosts":{"email":[],"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-03-01 03:13:41","updated":"2026-05-04 17:42:05"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/cliniqueomicron.ca\/en\" title=\"Accueil\">Accueil<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u203a<\/span><span class=\"aioseo-breadcrumb\">\n\tCancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Accueil","link":"https:\/\/cliniqueomicron.ca\/en"},{"label":"Cancer de la peau : m\u00e9lanome, carcinome basocellulaire et spinocellulaire | Clinique Omicron","link":"https:\/\/cliniqueomicron.ca\/en\/cancer-peau\/"}],"_links":{"self":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/comments?post=24413"}],"version-history":[{"count":4,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24413\/revisions"}],"predecessor-version":[{"id":27823,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24413\/revisions\/27823"}],"wp:attachment":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/media?parent=24413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}